Browse studies

Find your next paid study

1,058 recruiting studies matching your filters

Prospective Evaluation of the Gut Microbiome and a Pilot Dietary Intervention in Patients With HR+/HER2- Breast Cancer Receiving Abemaciclib (GEMMA)

This study will be conducted in 2 sequential parts. The first part will be a prospective, observational study. This will be followed by a small interventional,…

Breast Cancer

Estimated

~$10 – $6,250

University of ChicagoNCT07553234

Phase 1

Phase I/II Study of Stereotactic Radiation and Abemaciclib With or Without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)

This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastati…

Brain MetastasesHR+ Metastatic Breast Cancer

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT04923542

Older Breast Cancer Patients: Risk for Cognitive Decline. The Thinking and Living With Cancer (TLC) Study

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition doma…

Cancer, BreastAge-related Cognitive DeclineCognitive Decline

Estimated

~$10 – $750

Georgetown UniversityNCT03451383

Biospecimen Acquisition From Human Subjects

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chem…

Prostate CancerBreast CancerColon Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00034216

Genomic Services Research Program

Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene varia…

Colon CancerBreast Cancer

Estimated

~$10 – $675

National Human Genome Research Institute (NHGRI)NCT02595957

Phase 1

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT…

Breast CancerAdvanced Solid Tumor

Estimated

~$10 – $7,500

BeOne MedicinesNCT07222267

Observational

EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer

In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in …

CancerBreast Cancer

Estimated

~$10 – $7,500

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)NCT07704476

Phase 3

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+…

Breast Neoplasms

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07060807

Phase 1

A Phase 1a "Window Trial" of Cannabidiol (CBD) For Breast Cancer Primary Tumors

This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. P…

Breast Cancer

Estimated

~$10 – $6,250

Medical University of South CarolinaNCT06148038

Phase 1

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and a…

Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more

Estimated

~$10 – $8,750

Avenzo Therapeutics, Inc.NCT05867251

Phase 3

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared wit…

Breast Cancer

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT05646862

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to…

Metastatic Breast CancerEnd of Life

Estimated

~$10 – $750

UNC Lineberger Comprehensive Cancer CenterNCT05440929